Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Amarin Corporation plcNASDAQ: AMRN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $4.67M fell 12.2% year over year, behind the -6.9% change in trailing-twelve-month research & development. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at -13.3% a year.

Context

  • Research & development amounted to 9.3% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -12.2% toward the trailing-twelve-month pace of -6.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.67M+0.1% QoQ
Last fiscal yearDec 2025
$19.81M-5.1% YoY
LTMMar 2026
$18.45M-6.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.2%——
1 year-5.1%——
3-year CAGR-13.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
19.81M USD
Year-over-year change
-5.1%
4-year CAGR
-9.3%

Research & Development vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.9% is the 6th highest of 10, against a peer median of +5.0%.
  • Research & development amounts to 8.6% of revenue for AMRN, versus a peer median of 4120.5%.
AMRN Competitors
Research & Development for AMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$152.7M USD+75.7%+85.3%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M USD-11.7%-0.1%489780.6%
DBVTDBV Technologies S.A.LTM Mar 2026$124.71M USD+42.2%+15.6%—
ENGNenGene Holdings Inc.LTM Apr 2026$98.75M USD+56.7%+82.8%—
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
ALTAltimmune, Inc.LTM Mar 2026$66.77M USD-12.8%-2.0%185483.3%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
KRROKorro Bio, Inc.LTM Mar 2026$58.79M USD-15.8%+15.8%1530.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M USD+19.0%+24.4%—
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
AMRNAmarin Corporation plcLTM Mar 2026$18.45M USD-6.9%-13.3%8.6%
Peer median (excluding AMRN) —+5.0%+15.7%4120.5%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue583.19M369.19M306.91M228.61M213.65M
Cost of Revenue121.33M126.71M141.37M147.23M92.78M
Gross Profit461.86M242.48M165.54M81.38M120.87M
Gross Margin79.2%65.7%53.9%35.6%56.6%
Research & Development29.31M30.41M22.22M20.87M19.81M
Selling, General & Admin408.33M304.42M199.94M152.31M115M
Operating Expenses451.36M348.35M222.16M173.18M134.81M
Depreciation & Amortization2.86M3.1M2.97M3.01M3.03M
EBITDA14.28M(100.69M)(50.7M)(74.18M)(33.01M)
EBITDA Margin2.4%-27.3%-16.5%-32.4%-15.5%
Operating Income10.5M(105.87M)(56.62M)(91.8M)(13.94M)
Operating Margin1.8%-28.7%-18.4%-40.2%-6.5%
Interest Income1.22M2.82M11.86M13.4M10.85M
Interest Expense129K15K8K7K7K
Other Income / Expenses789K2.06M2.95M14.6M(22.11M)
Income Before Tax11.29M(103.81M)(53.67M)(77.2M)(36.05M)
Pre-Tax Margin1.9%-28.1%-17.5%-33.8%-16.9%
Income Tax Expense3.56M2M5.44M4.98M2.75M
Net Income7.73M(105.8M)(59.11M)(82.18M)(38.8M)
Net Margin1.3%-28.7%-19.3%-35.9%-18.2%
EPS (Basic)0.39(5.20)(3.00)(4.00)(1.80)
EPS (Diluted)0.38(5.20)(3.00)(4.00)(1.80)
Weighted Avg Shares19.8M20.06M19.7M20.55M20.75M
Weighted Avg Shares (Diluted)20.12M20.06M20.38M20.55M20.75M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.